TP53 and diffuse large B-cell lymphoma: Indeed, while MDM2 oncoprotein overexpression appears common in DLBCL irrespective of TP53 status, overexpression may not be as frequent in indolent lymphoma [107], suggesting that targeting this part of the MDM2-P53 signalling pathway may be insufficient in the indolent lymphoma context.